GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PeptiDream Inc (TSE:4587) » Definitions » COGS-to-Revenue

PeptiDream (TSE:4587) COGS-to-Revenue : 0.65 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is PeptiDream COGS-to-Revenue?

PeptiDream's Cost of Goods Sold for the three months ended in Mar. 2025 was 円2,765 Mil. Its Revenue for the three months ended in Mar. 2025 was 円4,233 Mil.

PeptiDream's COGS to Revenue for the three months ended in Mar. 2025 was 0.65.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. PeptiDream's Gross Margin % for the three months ended in Mar. 2025 was 34.69%.


PeptiDream COGS-to-Revenue Historical Data

The historical data trend for PeptiDream's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PeptiDream COGS-to-Revenue Chart

PeptiDream Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.25 0.33 0.40 0.26

PeptiDream Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.11 0.53 0.61 0.65

PeptiDream COGS-to-Revenue Calculation

PeptiDream's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=12172.699 / 46676.523
=0.26

PeptiDream's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2764.627 / 4233.246
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PeptiDream  (TSE:4587) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

PeptiDream's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 2764.627 / 4233.246
=34.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


PeptiDream COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of PeptiDream's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PeptiDream Business Description

Traded in Other Exchanges
Address
1-2-10, Nihonbashi, Chuo-ku, Toyo Building, 6th Floor, Tokyo, JPN, 103-0027
PeptiDream Inc is a biopharmaceutical company, engaged in the research and development of new pharmaceutical candidates. It discovers constrained peptides, small molecules, and peptide-drug conjugate therapeutics using its Peptide Discovery Platform System. The company aspires to be a leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.

PeptiDream Headlines

No Headlines